NSCLC phenotype

Aliases

Non‑small cell lung cancer, non-small cell lung cancer, non‑small cell lung cancer

No related entities found.

Mentioned in (32)

Papers in which this entity is mentioned.

• Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases. (2025)
• ENPP1 Immunobiology as a Therapeutic Target. (2023)
• Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. (2023)
• A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns. (2023)
• Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. (2023)
• Towards understandings of serine/arginine-rich splicing factors. (2023)
• Genome-wide mutational signatures in low-coverage whole genome sequencing of cell-free DNA. (2022)
• Spatially resolved whole transcriptome profiling in human and mouse tissue using Digital Spatial Profiling. (2022)
• Inferring gene expression from cell-free DNA fragmentation profiles. (2022)
• Detection and characterization of lung cancer using cell-free DNA fragmentomes. (2021)
• Macrophage Polarization States in the Tumor Microenvironment. (2021)
• TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. (2021)
• Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. (2021)
• Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. (2020)
• Neoadjuvant checkpoint blockade for cancer immunotherapy. (2020)
• Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. (2020)
• Determining cell type abundance and expression from bulk tissues with digital cytometry. (2019)
• Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. (2019)
• Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in -rearranged lung cancer. (2019)
• Genome doubling shapes the evolution and prognosis of advanced cancers. (2018)
• Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. (2017)
• OncoKB: A Precision Oncology Knowledge Base. (2017)
• Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. (2017)
• Integrated digital error suppression for improved detection of circulating tumor DNA. (2016)
• MBASED: allele-specific expression detection in cancer tissues and cell lines. (2014)
• Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. (2014)
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. (2014)
• Clonal evolution in hematological malignancies and therapeutic implications. (2014)
• DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. (2013)
• Cancer genome landscapes. (2013)
• A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. (2013)
• Patient-derived tumour xenografts as models for oncology drug development. (2012)

Merged raw entities (2)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.